ATE66143T1 - Feste zubereitung mit langsamer freisetzung. - Google Patents

Feste zubereitung mit langsamer freisetzung.

Info

Publication number
ATE66143T1
ATE66143T1 AT85300215T AT85300215T ATE66143T1 AT E66143 T1 ATE66143 T1 AT E66143T1 AT 85300215 T AT85300215 T AT 85300215T AT 85300215 T AT85300215 T AT 85300215T AT E66143 T1 ATE66143 T1 AT E66143T1
Authority
AT
Austria
Prior art keywords
slow release
solid preparation
release solid
sodium
alginate
Prior art date
Application number
AT85300215T
Other languages
English (en)
Inventor
Rodney Dr Horder
Michel Dr Banks
Thomas Herbert Hoadley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE66143T1 publication Critical patent/ATE66143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
AT85300215T 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung. ATE66143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19850300215 EP0188040B1 (de) 1985-01-11 1985-01-11 Feste Zubereitung mit langsamer Freisetzung

Publications (1)

Publication Number Publication Date
ATE66143T1 true ATE66143T1 (de) 1991-08-15

Family

ID=8194116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85300215T ATE66143T1 (de) 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung.

Country Status (7)

Country Link
US (1) US4842866A (de)
EP (1) EP0188040B1 (de)
AT (1) ATE66143T1 (de)
CA (1) CA1273873A (de)
DE (1) DE3583799D1 (de)
ES (1) ES8705757A1 (de)
GR (1) GR860060B (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
CA1302659C (en) * 1986-10-24 1992-06-09 Hans-Peter K. Gribi Dental impression material
EP0275336A1 (de) * 1987-01-20 1988-07-27 Knoll Ag Arzneimittelzubereitung mit protahierender Wirkung
US5064736A (en) * 1988-03-23 1991-11-12 Olin Corporation Electrostatic method for multicolor imaging from a single toner bath
DE4002281A1 (de) * 1990-01-26 1991-08-01 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit dem wirkstoff tulobuterol
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
FR2676364B1 (fr) * 1991-05-17 1993-09-10 Lafon Labor Composition pharmaceutique a base de derives d'aminobutanone.
US5368862A (en) * 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5670169A (en) * 1993-12-20 1997-09-23 E.R. Squibb & Sons, Inc. Wound hydrating gel with novel preservative system and low cytotoxicity
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
DE4443358A1 (de) * 1994-12-06 1996-06-13 Basf Ag Depot-Arzneimittel
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6010718A (en) 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20108B (en) * 1997-06-11 2001-12-31 Abbott Lab A controlled release formulation for poorly soluble basic drugs
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
BG65116B1 (bg) * 2000-01-06 2007-03-30 Abbott Laboratories Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
RU2200002C1 (ru) * 2001-07-30 2003-03-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Твердая фармацевтическая композиция и способ ее получения
CA2405918A1 (en) * 2001-10-01 2003-04-01 Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
EP1443910A1 (de) * 2001-11-02 2004-08-11 Wockhardt Limited Zubereitungen mit kontrollierter freigabe von makrolidantibiotika
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP1638529B1 (de) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Orale zusammensetzung mit verlängerter freisetzung
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2617150C (en) * 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8030356B2 (en) 2006-03-17 2011-10-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2010516680A (ja) 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
CN104119310B (zh) * 2007-09-26 2017-04-12 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物
PT2234607E (pt) * 2007-12-28 2011-09-30 Acraf Formulação de libertação lenta com base numa associação de glicogénio e alginato
EP3067352A3 (de) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Neuartige nitrosoverbindungen als nitroxyldonatoren und verfahren zur verwendung davon
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
RU2576033C2 (ru) 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
US20120082719A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
PL2625176T3 (pl) 2010-10-08 2017-08-31 Xcovery Holding Company Llc Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
SG10201802862WA (en) 2013-01-18 2018-05-30 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
EP2983702A2 (de) 2013-04-07 2016-02-17 The Broad Institute, Inc. Zusammensetzungen und verfahren für personalisierte neoplasieimpfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
EP3148972B1 (de) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolonderivate als nitroxyldonatoren
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10202363B2 (en) 2014-12-23 2019-02-12 Cerecor, Inc. Compounds, compositions and methods
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
CN107750160B (zh) 2015-06-09 2021-06-22 百缮药业(苏州)有限公司 氟代环戊烯基胞嘧啶的用途及制备方法
KR101592144B1 (ko) 2015-06-19 2016-02-04 고려대학교 산학협력단 요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
WO2017040980A2 (en) 2015-09-04 2017-03-09 Rexahn Pharmaceuticals, Inc. Quinoxalinyl-piperazinamide methods of use
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
MX390005B (es) 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112020022294A2 (pt) 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
EP3955923A1 (de) 2019-04-18 2022-02-23 The Regents Of The University Of Michigan Kombination mit checkpoint-inhibitoren zur behandlung von krebs
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2021242793A2 (en) 2020-05-26 2021-12-02 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
EP4161508A1 (de) 2020-06-05 2023-04-12 Henry Ford Health System Dakalasvir zur verwendung bei der behandlung von lungen- und prostatakrebs
US20240239764A1 (en) 2020-12-22 2024-07-18 Mekanistic Therapeutics Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
EP4385510A4 (de) 2021-08-10 2025-08-20 Betta Pharmaceuticals Co Ltd Verwendung von ensartinib oder einem salz davon bei der behandlung von krankheiten mit exon-skipping-mutation von met 14
EP4426829A1 (de) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologisch ausgewählte bibliotheken künstlicher miniproteome von nukleinsäuren
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR985218A (fr) * 1948-04-27 1951-07-16 Medical Alginates Ltd Perfectionnements aux procédé d'application des produits alginatés
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
DE2062715C3 (de) * 1970-12-19 1974-03-21 Efeka Friedrich & Kaufmann Arzneimittelfabrik, 3000 Hannover Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2971660B2 (ja) * 1991-03-29 1999-11-08 株式会社東芝 超電導磁石装置
JP3000771B2 (ja) * 1991-12-20 2000-01-17 株式会社日立製作所 磁気浮上式走行体とその走行安定方法

Also Published As

Publication number Publication date
US4842866A (en) 1989-06-27
ES550807A0 (es) 1987-05-16
EP0188040B1 (de) 1991-08-14
CA1273873A (en) 1990-09-11
ES8705757A1 (es) 1987-05-16
DE3583799D1 (de) 1991-09-19
GR860060B (en) 1986-05-12
EP0188040A1 (de) 1986-07-23

Similar Documents

Publication Publication Date Title
ATE66143T1 (de) Feste zubereitung mit langsamer freisetzung.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
ZA894728B (en) A new pharmaceutical formulation as well as a process for its preparation
IL78111A0 (en) Sulfur-containing 5-substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
FI863074A7 (fi) Farmaseuttisesti aktiivisten aineiden rakeinen, hidasluovutteinen muoto.
FI882888A7 (fi) Liuottimettomilla reaktioilla valmistettavia oksaskopolymeereja ja nii den dispergoivia johdannaisia.
IL78970A (en) 3-(heteroaralkylamino-alkyl)-3-benzazepin-2-one derivatives,their preparation and pharmaceutical compositions containing them
DK143588A (da) Substituerede 9-amino-tetrahydroacridiner, deres fremstilling og anvendelse som laegemidler
IL89205A (en) Chloroaniline derivatives, their preparation and pharmaceutical compositions containing them
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
NL970029I2 (nl) Benzimidazoolderivaten, bereiding en therapeutische toepassing.
EP0380021A3 (de) Stabilisierungssystem für feste Dosisformen
ES491307A0 (es) Un procedimiento para la preparacion de una composicion de liberacion controlada de un compuesto biologicamente activo para su administracion a un animal
IL80229A0 (en) Flavone derivatives,their preparation and pharmaceutical compositions containing them
FI864164A7 (fi) Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
DK366888A (da) Castanosperminestre og -glykosider, deres fremstilling og anvendelse som laegemidler
ZA872739B (en) Benzimidazolesulfonamides and imidazopyridine-sulfonamides,their preparation and their application as drugs
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
DK284688D0 (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler
FI880210L (fi) Menetelmä valmistaa peroraalista stabiloitua, tehoainetta hidastetusti ja kontrolloidusti vapauttavaa, lääkevalmistetta
IL85651A0 (en) Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them
AU7111587A (en) Perhydrothiazepine and perhydroazepine derivatives,their preparation and their therapeutic use
DK469087D0 (da) Farmaceutisk praeparat indeholdende et calciumoptagelsesblokerende middel og en ace-inhibitor.
FI883730A7 (fi) Eetterit ja tioeetterit, joilla on terapeuttinen vaikutus, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time